WT1 peptide-based cancer vaccine in patients with high risk rhabdomyosarcoma, a multicenter, phase 2 clinical study
Phase 2
- Conditions
- rhabdomyosarcoma
- Registration Number
- JPRN-UMIN000013325
- Lead Sponsor
- Osaka university graduate school of medicine Pediatrics
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 33
Inclusion Criteria
Not provided
Exclusion Criteria
1.Active bacterial or fungal infection 2.Severe complications 3.MDS, MDS/MPD, MPD 4.Inadequate physical condition, as diagnosed by the primary physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 2 year relapse rate
- Secondary Outcome Measures
Name Time Method 2 year progression free rate safety over all survival immunological monitering